{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:19:15Z","timestamp":1792783155727,"version":"4.5.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:00:00Z","timestamp":1789776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:00:00Z","timestamp":1789776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universidade Federal De S\u00e3o Paulo","id":[{"id":"https:\/\/ror.org\/02k5swt12","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cell Biochem"],"DOI":"10.1007\/s11010-026-05747-z","type":"journal-article","created":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T09:57:21Z","timestamp":1789811841000},"page":"5577-5590","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["NRF2 signaling drives chemoresistance in NSCLC and glioblastoma"],"prefix":"10.1007","volume":"481","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6935-7521","authenticated-orcid":false,"given":"Izadora","family":"de Souza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda Karolynne Seregni","family":"Monteiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2659-6714","authenticated-orcid":false,"given":"Ana Beatriz","family":"da Silva Teixeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila Banca","family":"Guedes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karoline Almeida","family":"Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e1udio Henrique Dahne","family":"de Souza Filho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izabela Am\u00e9lia Marques","family":"de Andrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Carolina Clares","family":"Ramalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz Silva","family":"de Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Lazarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7090-0832","authenticated-orcid":false,"given":"Clarissa Ribeiro Reily","family":"Rocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,19]]},"reference":[{"key":"5747_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A (2025) Cancer statistics, 2025. CA Cancer J Clin 75:10\u201345. https:\/\/doi.org\/10.3322\/caac.21871","journal-title":"CA Cancer J Clin"},{"key":"5747_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A (2023) Cancer statistics, 2023. Cancer J Clin 73:17\u201348. https:\/\/doi.org\/10.3322\/caac.21763","journal-title":"Cancer J Clin"},{"key":"5747_CR3","doi-asserted-by":"publisher","first-page":"288","DOI":"10.21037\/tlcr.2016.06.07","volume":"5","author":"C Zappa","year":"2016","unstructured":"Zappa C, Mousa SA (2016) Non-small cell lung cancer: current treatment and future advances. Translational Lung Cancer Res 5:288\u2013300. https:\/\/doi.org\/10.21037\/tlcr.2016.06.07","journal-title":"Translational Lung Cancer Res"},{"key":"5747_CR4","doi-asserted-by":"publisher","unstructured":"OS B et al (2001) Twenty-two years of phase III trials for patients with advanced non-small-cell. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.2001.19.6.1734","DOI":"10.1200\/JCO.2001.19.6.1734"},{"key":"5747_CR5","doi-asserted-by":"crossref","unstructured":"JR M, SE PYSDC, S., AA A (2008) - Non-small cell lung cancer: epidemiology, risk factors, treatment, and. - Mayo Clin Proc. doi: 10.4065\/83.5.584., T - ppublish","DOI":"10.4065\/83.5.584"},{"key":"5747_CR6","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ctrv.2016.01.003","volume":"44","author":"DA Fennell","year":"2016","unstructured":"Fennell DA et al (2016) Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer. Cancer Treat Rev 44:42\u201350. https:\/\/doi.org\/10.1016\/j.ctrv.2016.01.003","journal-title":"Cancer Treat Rev"},{"key":"5747_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/biom12101365","volume":"12","author":"Y Lugones","year":"2022","unstructured":"Lugones Y, Loren P, Salazar LA (2022) Cisplatin resistance: genetic and epigenetic factors involved. Biomolecules 12:1365. https:\/\/doi.org\/10.3390\/biom12101365","journal-title":"Biomolecules"},{"key":"5747_CR8","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1007\/s12272-021-01312-y","volume":"44","author":"H-Y Min","year":"2021","unstructured":"Min H-Y, Lee H-Y (2021) Mechanisms of resistance to chemotherapy in non-small cell lung cancer. Arch Pharm Res 44:146\u2013164. https:\/\/doi.org\/10.1007\/s12272-021-01312-y","journal-title":"Arch Pharm Res"},{"key":"5747_CR9","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1001\/jamaneurol.2014.1701","volume":"71","author":"AA Thomas","year":"2014","unstructured":"Thomas AA, Brennan CW, DeAngelis LM, Omuro AM (2014) Emerging Therapies for Glioblastoma. JAMA Neurol 71:1437\u20131444. https:\/\/doi.org\/10.1001\/jamaneurol.2014.1701","journal-title":"JAMA Neurol"},{"key":"5747_CR10","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1080\/15384047.2019.1599662","volume":"20","author":"A Arora","year":"2019","unstructured":"Arora A, Somasundaram K (2019) Glioblastoma vs temozolomide: can the red queen race be won? Cancer Biol Ther 20:1083\u20131090. https:\/\/doi.org\/10.1080\/15384047.2019.1599662","journal-title":"Cancer Biol Ther"},{"key":"5747_CR11","doi-asserted-by":"publisher","first-page":"513","DOI":"10.2174\/1570159X18666200626204005","volume":"19","author":"R Ortiz","year":"2021","unstructured":"Ortiz R et al (2021) Temozolomide: An Updated Overview of Resistance Mechanisms, Nanotechnology Advances and Clinical Applications. Curr Neuropharmacol 19:513\u2013537. https:\/\/doi.org\/10.2174\/1570159X18666200626204005","journal-title":"Curr Neuropharmacol"},{"key":"5747_CR12","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/nejmoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R et al (2005) Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. N Engl J Med 352:987\u2013996. https:\/\/doi.org\/10.1056\/nejmoa043330","journal-title":"N Engl J Med"},{"key":"5747_CR13","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.gendis.2016.04.007","volume":"3","author":"SY Lee","year":"2016","unstructured":"Lee SY (2016) Temozolomide resistance in glioblastoma multiforme. Genes Dis 3:198\u2013210. https:\/\/doi.org\/10.1016\/j.gendis.2016.04.007","journal-title":"Genes Dis"},{"key":"5747_CR14","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3322\/caac.21693","volume":"71","author":"KD Miller","year":"2021","unstructured":"Miller KD et al (2021) Brain and other central nervous system tumor statistics, 2021. Cancer J Clin 71:381\u2013406. https:\/\/doi.org\/10.3322\/caac.21693","journal-title":"Cancer J Clin"},{"key":"5747_CR15","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/nrc1529","volume":"5","author":"BA Chabner","year":"2005","unstructured":"Chabner BA, Roberts TG (2005) Chemotherapy and the war on cancer. Nat Rev Cancer 5:65\u201372. https:\/\/doi.org\/10.1038\/nrc1529","journal-title":"Nat Rev Cancer"},{"key":"5747_CR16","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","volume":"740","author":"S Dasari","year":"2014","unstructured":"Dasari S, Bernard Tchounwou P (2014) Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol 740:364\u2013378. https:\/\/doi.org\/10.1016\/j.ejphar.2014.07.025","journal-title":"Eur J Pharmacol"},{"key":"5747_CR17","doi-asserted-by":"publisher","unstructured":"Garc\u00eda Mart\u00edn M et al (2009) Critical appraisal of temozolomide formulations in the treatment of primary brain tumors: patient considerations. Cancer Manage Res 137. https:\/\/doi.org\/10.2147\/cmr.s5598","DOI":"10.2147\/cmr.s5598"},{"key":"5747_CR18","doi-asserted-by":"publisher","first-page":"68","DOI":"10.4103\/glioma.glioma_3_19","volume":"2","author":"P Woo","year":"2019","unstructured":"Woo P et al (2019) A multifaceted review of temozolomide resistance mechanisms in glioblastoma beyond O-6-methylguanine-DNA methyltransferase. Glioma (Mumbai India) 2:68\u201382. https:\/\/doi.org\/10.4103\/glioma.glioma_3_19","journal-title":"Glioma (Mumbai India)"},{"key":"5747_CR19","doi-asserted-by":"publisher","first-page":"e1257","DOI":"10.1038\/cddis.2013.428","volume":"5","author":"L Galluzzi","year":"2014","unstructured":"Galluzzi L et al (2014) Systems biology of cisplatin resistance: past, present and future. Cell Death Dis 5:e1257. https:\/\/doi.org\/10.1038\/cddis.2013.428","journal-title":"Cell Death Dis"},{"key":"5747_CR20","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1101\/gad.225680.113","volume":"27","author":"C Jaramillo","year":"2013","unstructured":"Jaramillo C, Zhang D (2013) The emerging role of the Nrf2-Keap1 signaling pathway in cancer. Genes Dev 27:2179\u20132191. https:\/\/doi.org\/10.1101\/gad.225680.113","journal-title":"Genes Dev"},{"key":"5747_CR21","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/nrc3278","volume":"12","author":"MB Sporn","year":"2012","unstructured":"Sporn MB, Liby KT (2012) NRF2 and cancer: the good, the bad and the importance of context. Nat Rev Cancer 12:564\u2013571. https:\/\/doi.org\/10.1038\/nrc3278","journal-title":"Nat Rev Cancer"},{"key":"5747_CR22","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.semcdb.2012.03.017","volume":"23","author":"H Zhang","year":"2012","unstructured":"Zhang H, Forman HJ (2012) Glutathione synthesis and its role in redox signaling. Semin Cell Dev Biol 23:722\u2013728. https:\/\/doi.org\/10.1016\/j.semcdb.2012.03.017","journal-title":"Semin Cell Dev Biol"},{"key":"5747_CR23","doi-asserted-by":"publisher","first-page":"e1505","DOI":"10.1038\/cddis.2014.465","volume":"5","author":"CRR Rocha","year":"2014","unstructured":"Rocha CRR et al (2014) Glutathione depletion sensitizes cisplatin- and temozolomide-resistant glioma cells in vitro and in vivo. Cell Death Dis 5:e1505\u2013e1505. https:\/\/doi.org\/10.1038\/cddis.2014.465","journal-title":"Cell Death Dis"},{"key":"5747_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2021.105136","volume":"149","author":"JA Campos-Sandoval","year":"2021","unstructured":"Campos-Sandoval JA et al (2021) Antioxidant responses related to temozolomide resistance in glioblastoma. Neurochem Int 149:105136. https:\/\/doi.org\/10.1016\/j.neuint.2021.105136","journal-title":"Neurochem Int"},{"key":"5747_CR25","doi-asserted-by":"publisher","first-page":"48081","DOI":"10.18632\/oncotarget.10129","volume":"7","author":"CR Reily Rocha","year":"2016","unstructured":"Reily Rocha CR, Kajitani S, Quinet GA, Fortunato S (2016) Martins Menck, C. F. NRF2 and glutathione are key resistance mediators to temozolomide in glioma and melanoma cells. Oncotarget 7:48081\u201348092. https:\/\/doi.org\/10.18632\/oncotarget.10129","journal-title":"Oncotarget"},{"key":"5747_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-54065-6","author":"MM Silva","year":"2019","unstructured":"Silva MM, Rocha CRR, Kinker GS, Pelegrini AL, Menck CFM (2019) The balance between NRF2\/GSH antioxidant mediated pathway and DNA repair modulates cisplatin resistance in lung cancer cells. Sci Rep. https:\/\/doi.org\/10.1038\/s41598-019-54065-6","journal-title":"Sci Rep"},{"key":"5747_CR27","doi-asserted-by":"publisher","first-page":"40461","DOI":"10.1074\/jbc.m110.164046","volume":"285","author":"W-B Zhang","year":"2010","unstructured":"Zhang W-B et al (2010) Activation of AMP-activated Protein Kinase by Temozolomide Contributes to Apoptosis in Glioblastoma Cells via p53 Activation and mTORC1 Inhibition. J Biol Chem 285:40461\u201340471. https:\/\/doi.org\/10.1074\/jbc.m110.164046","journal-title":"J Biol Chem"},{"key":"5747_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11041081","volume":"11","author":"K Almeida Lima","year":"2023","unstructured":"Almeida Lima K et al (2023) Temozolomide resistance in glioblastoma by NRF2: protecting the evil. Biomedicines 11:1081. https:\/\/doi.org\/10.3390\/biomedicines11041081","journal-title":"Biomedicines"},{"key":"5747_CR29","doi-asserted-by":"publisher","unstructured":"S M et al (2021) Nrf2 signaling pathway in cisplatin chemotherapy: Potential involvement in organ. Pharmacol Res. https:\/\/doi.org\/10.1016\/j.phrs.2021.105575","DOI":"10.1016\/j.phrs.2021.105575"},{"key":"5747_CR30","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1124\/mol.59.4.837","volume":"59","author":"K Zhang","year":"2001","unstructured":"Zhang K, Chew M, Yang EB, Wong KP, Mack P (2001) Modulation of Cisplatin Cytotoxicity and Cisplatin-Induced DNA Cross-Links in HepG2 Cells by Regulation of Glutathione-Related Mechanisms. Mol Pharmacol 59:837\u2013843. https:\/\/doi.org\/10.1124\/mol.59.4.837","journal-title":"Mol Pharmacol"},{"key":"5747_CR31","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/bf02390175","volume":"11","author":"MJ Allalunis-Turner","year":"1991","unstructured":"Allalunis-Turner MJ et al (1991) Glutathione levels and chemosensitizing effects of buthionine sulfoximine in human malignant glioma cells. J Neurooncol 11:157\u2013164. https:\/\/doi.org\/10.1007\/bf02390175","journal-title":"J Neurooncol"},{"key":"5747_CR32","doi-asserted-by":"publisher","unstructured":"KS L et al (1992) Effects of buthionine sulfoximine treatment on cellular glutathione levels and. Korean J Intern Med. https:\/\/doi.org\/10.3904\/kjim.1992.7.2.111","DOI":"10.3904\/kjim.1992.7.2.111"},{"key":"5747_CR33","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1007\/s10103-003-0269-3","volume":"18","author":"F Jiang","year":"2003","unstructured":"Jiang F et al (2003) Photodynamic therapy with photofrin in combination with Buthionine Sulfoximine (BSO) of human glioma in the nude rat. Lasers Med Sci 18:128\u2013133. https:\/\/doi.org\/10.1007\/s10103-003-0269-3","journal-title":"Lasers Med Sci"},{"key":"5747_CR34","unstructured":"OW G, A M (1979) - Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine. - J Biol Chem. T - ppublish"},{"key":"5747_CR35","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1002\/1097-0347(200012)22:8<748::AID-HED2>3.0.CO;2-6","volume":"22","author":"T Kato","year":"2000","unstructured":"Kato T et al (2000) Cisplatin and radiation sensitivity in human head and neck squamous carcinomas are independently modulated by glutathione and transcription factor NF-kappaB. Head Neck 22:748","journal-title":"Head Neck"},{"key":"5747_CR36","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.1016\/0006-2952(85)90551-9","volume":"34","author":"TC Hamilton","year":"1985","unstructured":"Hamilton TC et al (1985) Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion. Biochem Pharmacol 34:2583\u20132586. https:\/\/doi.org\/10.1016\/0006-2952(85)90551-9","journal-title":"Biochem Pharmacol"},{"key":"5747_CR37","doi-asserted-by":"crossref","unstructured":"EP S et al (2001) - L-buthionine sulfoximine potentiates the antitumor effect of. - Neurosurgery. doi: 10.1097\/00006123-200102000-00032., T - ppublish","DOI":"10.1097\/00006123-200102000-00032"},{"key":"5747_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-0794-4","author":"Y Sun","year":"2018","unstructured":"Sun Y, Zheng Y, Wang C, Liu Y (2018) Glutathione depletion induces ferroptosis, autophagy, and premature cell senescence in retinal pigment epithelial cells. Cell Death Dis. https:\/\/doi.org\/10.1038\/s41419-018-0794-4","journal-title":"Cell Death Dis"},{"key":"5747_CR39","doi-asserted-by":"publisher","first-page":"474","DOI":"10.3892\/ol.2015.3879","volume":"11","author":"Q Li","year":"2016","unstructured":"Li Q et al (2016) The effects of buthionine sulfoximine on the proliferation and apoptosis of biliary tract cancer cells induced by cisplatin and gemcitabine. Oncol Lett 11:474\u2013480. https:\/\/doi.org\/10.3892\/ol.2015.3879","journal-title":"Oncol Lett"},{"key":"5747_CR40","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1006\/abbi.1998.1067","volume":"363","author":"Y Higuchi","year":"1999","unstructured":"Higuchi Y, Matsukawa S (1999) Glutathione depletion induces giant DNA and high-molecular-weight DNA fragmentation associated with apoptosis through lipid peroxidation and protein kinase C activation in C6 glioma cells. Arch Biochem Biophys 363:33\u201342. https:\/\/doi.org\/10.1006\/abbi.1998.1067","journal-title":"Arch Biochem Biophys"},{"key":"5747_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05044-9","author":"I De Souza","year":"2022","unstructured":"De Souza I et al (2022) High levels of NRF2 sensitize temozolomide-resistant glioblastoma cells to ferroptosis via ABCC1\/MRP1 upregulation. Cell Death Dis. https:\/\/doi.org\/10.1038\/s41419-022-05044-9","journal-title":"Cell Death Dis"},{"key":"5747_CR42","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1002\/path.1706","volume":"205","author":"D Longley","year":"2005","unstructured":"Longley D, Johnston P (2005) Molecular mechanisms of drug resistance. J Pathol 205:275\u2013292. https:\/\/doi.org\/10.1002\/path.1706","journal-title":"J Pathol"},{"key":"5747_CR43","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1093\/carcin\/bgn095","volume":"29","author":"X-J Wang","year":"2008","unstructured":"Wang X-J et al (2008) Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. Carcinogenesis 29:1235\u20131243. https:\/\/doi.org\/10.1093\/carcin\/bgn095","journal-title":"Carcinogenesis"},{"key":"5747_CR44","doi-asserted-by":"publisher","DOI":"10.2147\/dddt.s106412","author":"X Zhu","year":"2016","unstructured":"Zhu X et al (2016) Molecular mechanisms of cisplatin resistance in cervical cancer. Drug Des Devel Ther. https:\/\/doi.org\/10.2147\/dddt.s106412","journal-title":"Drug Des Devel Ther"},{"key":"5747_CR45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0081162","volume":"8","author":"R Marullo","year":"2013","unstructured":"Marullo R et al (2013) Cisplatin induces a mitochondrial-ROS response that contributes to cytotoxicity depending on mitochondrial redox status and bioenergetic functions. PLoS One 8:e81162. https:\/\/doi.org\/10.1371\/journal.pone.0081162","journal-title":"PLoS One"},{"key":"5747_CR46","doi-asserted-by":"publisher","first-page":"102","DOI":"10.2174\/1874467211205010102","volume":"5","author":"J Zhang","year":"2012","unstructured":"Zhang J, Stevens MFG, Bradshaw TD (2012) Temozolomide: mechanisms of action, repair and resistance. Curr Mol Pharmacol 5:102\u2013114. https:\/\/doi.org\/10.2174\/1874467211205010102","journal-title":"Curr Mol Pharmacol"},{"key":"5747_CR47","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1186\/s13046-018-0909-x","volume":"37","author":"H Yang","year":"2018","unstructured":"Yang H et al (2018) The role of cellular reactive oxygen species in cancer chemotherapy. J experimental Clin cancer Res 37:266\u2013210. https:\/\/doi.org\/10.1186\/s13046-018-0909-x","journal-title":"J experimental Clin cancer Res"},{"key":"5747_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/972913","volume":"2013","author":"N Traverso","year":"2013","unstructured":"Traverso N et al (2013) Role of glutathione in cancer progression and chemoresistance. Oxid Med Cell Longev 2013:1\u201310. https:\/\/doi.org\/10.1155\/2013\/972913","journal-title":"Oxid Med Cell Longev"},{"key":"5747_CR49","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.freeradbiomed.2008.10.040","volume":"46","author":"CJ Harvey","year":"2009","unstructured":"Harvey CJ et al (2009) Nrf2-regulated glutathione recycling independent of biosynthesis is critical for cell survival during oxidative stress. Free Radic Biol Med 46:443\u2013453. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2008.10.040","journal-title":"Free Radic Biol Med"},{"key":"5747_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/cells9122573","volume":"9","author":"CRR Rocha","year":"2020","unstructured":"Rocha CRR et al (2020) Revealing temozolomide resistance mechanisms via genome-wide CRISPR libraries. Cells 9:2573. https:\/\/doi.org\/10.3390\/cells9122573","journal-title":"Cells"},{"key":"5747_CR51","doi-asserted-by":"publisher","first-page":"7473","DOI":"10.1038\/s41388-019-0956-6","volume":"38","author":"P P\u00f6l\u00f6nen","year":"2019","unstructured":"P\u00f6l\u00f6nen P et al (2019) Nrf2 and SQSTM1\/p62 jointly contribute to mesenchymal transition and invasion in glioblastoma. Oncogene 38:7473\u20137490. https:\/\/doi.org\/10.1038\/s41388-019-0956-6","journal-title":"Oncogene"},{"key":"5747_CR52","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3389\/fonc.2017.00085","volume":"7","author":"K Taguchi","year":"2017","unstructured":"Taguchi K, Yamamoto M (2017) The KEAP1-NRF2 System in Cancer. Front Oncol 7:85\u201385. https:\/\/doi.org\/10.3389\/fonc.2017.00085","journal-title":"Front Oncol"},{"key":"5747_CR53","doi-asserted-by":"publisher","first-page":"3423","DOI":"10.1158\/1078-0432.ccr-08-2822","volume":"15","author":"S Homma","year":"2009","unstructured":"Homma S et al (2009) Nrf2 Enhances Cell Proliferation and Resistance to Anticancer Drugs in Human Lung Cancer. Clin Cancer Res 15:3423\u20133432. https:\/\/doi.org\/10.1158\/1078-0432.ccr-08-2822","journal-title":"Clin Cancer Res"},{"key":"5747_CR54","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22094376","volume":"22","author":"M-Y Song","year":"2021","unstructured":"Song M-Y, Lee D-Y, Chun K-S, Kim E-H (2021) The role of NRF2\/KEAP1 signaling pathway in cancer metabolism. Int J Mol Sci 22:4376. https:\/\/doi.org\/10.3390\/ijms22094376","journal-title":"Int J Mol Sci"},{"key":"5747_CR55","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1002\/pbc.25994","volume":"63","author":"JG Villablanca","year":"2016","unstructured":"Villablanca JG et al (2016) A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent\/Refractory High-Risk Neuroblastoma. Pediatr Blood Cancer 63:1349\u20131356. https:\/\/doi.org\/10.1002\/pbc.25994","journal-title":"Pediatr Blood Cancer"},{"key":"5747_CR56","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S0009-2797(98)00008-8","volume":"111","author":"P Calvert","year":"1998","unstructured":"Calvert P, Yao K-S, Hamilton TC, O\u2019Dwyer PJ (1998) Clinical studies of reversal of drug resistance based on glutathione. Chemico-Biol Interact 111:213\u2013224. https:\/\/doi.org\/10.1016\/S0009-2797(98)00008-8","journal-title":"Chemico-Biol Interact"},{"key":"5747_CR57","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0163-7258(91)90076-X","volume":"51","author":"A Meister","year":"1991","unstructured":"Meister A (1991) Glutathione deficiency produced by inhibition of its synthesis, and its reversal Applications in research and therapy. Pharmacol Ther (Oxford) 51:155\u2013194. https:\/\/doi.org\/10.1016\/0163-7258(91)90076-X","journal-title":"Pharmacol Ther (Oxford)"},{"key":"5747_CR58","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/S0076-6879(85)13073-9","volume":"113","author":"ME Anderson","year":"1985","unstructured":"Anderson ME (1985) [70] Determination of glutathione and glutathione disulfide in biological samples. Methods Enzymol 113:548\u2013555. https:\/\/doi.org\/10.1016\/S0076-6879(85)13073-9","journal-title":"Methods Enzymol"},{"key":"5747_CR59","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","volume":"149","author":"J Dixon","year":"2012","unstructured":"Dixon J, Scott et al (2012) Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death. Cell 149:1060\u20131072. https:\/\/doi.org\/10.1016\/j.cell.2012.03.042","journal-title":"Cell"},{"key":"5747_CR60","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1146\/annurev-cancerbio-030518-055844","volume":"3","author":"SJ Dixon","year":"2019","unstructured":"Dixon SJ, Stockwell BR (2019) The Hallmarks of Ferroptosis. Annual Rev Cancer Biology 3:35\u201354. https:\/\/doi.org\/10.1146\/annurev-cancerbio-030518-055844","journal-title":"Annual Rev Cancer Biology"}],"container-title":["Molecular and Cellular Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-026-05747-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11010-026-05747-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-026-05747-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T07:55:30Z","timestamp":1792569330000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11010-026-05747-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,19]]},"references-count":60,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["5747"],"URL":"https:\/\/doi.org\/10.1007\/s11010-026-05747-z","relation":{},"ISSN":["1573-4919"],"issn-type":[{"value":"1573-4919","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,19]]},"assertion":[{"value":"23 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}